產(chǎn)品屬性：
產(chǎn)品名稱 | PTPN22-IN-1 |
規(guī)格 | 5 mg、10 mg、25 mg |
貨號(hào) | EY-01Y18111 |
Cas No.: 2580935-57-3
別名: N/A
化學(xué)名: N/A
分子式: C26H21N3O5
分子量: 455.46
溶解度: N/A
儲(chǔ)存條件: Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
PTPN22-IN-1 is a potent PTPN22 inhibitor (IC50=1.4 μM; Ki=0.50 μM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses[1]. From WO2021007491A1 compound L-1.PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and Cmax of 1.1 1 μM (Fig. 9d), which is more than twice of its Ki value[1].PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and Cmax of 1.1 1 μM (Fig. 9d), which is more than twice of its Ki value[1].[1]. Elizabeth Jaffee, et al. Targeting ptpn22 in cancer therapy. WO2021007491A1.
特別提醒公司產(chǎn)品僅供科研使用
